VEGF靶向治疗及其生物标志物在晚期结直肠癌中的研究进展

VEGF-targeted therapy for metastatic colorectal cancer and related biomarkers: recent advances

摘要:

结直肠癌（CRC）是世界范围内癌症发病与致死的主要因素，近几年分子靶向治疗的临床应用为晚期结直肠癌治疗带来了曙光。贝伐珠单抗被批准应用于一线和二线晚期结直肠癌的治疗，促使了以血管内皮生长因子（VEGF）为作用靶点的靶向治疗药物不断涌现，并在临床试验中取得显著疗效。笔者就VEGF靶向治疗及其生物标志物在晚期结直肠癌中的研究进展进行综述。

Abstract:

Colorectal cancer (CRC) is a major contributor to cancer morbidity and mortality worldwide. Recently, the clinical application of molecular targeting therapy brings hope for treatment of metastatic CRC (mCRC). Following the approval of bevacizumab as first- and second-line treatment of mCRC, the therapeutic agents targeting vascular endothelial growth factor (VEGF) have been emerging constantly, and also shown significant efficacy in clinical trials. In this paper, the authors address the progress in VEGF-targeted therapy and the related biomarkers for mCRC.